valproic acid has been researched along with epirubicin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fischer, T; Fleischer, B; Galle, PR; Lohse, AW; Schattenberg, JM; Schuchmann, M; Schulze-Bergkamen, H; Siebler, J; Strand, S; Teufel, A; Weinmann, A; Wörns, M | 1 |
| Bicaku, E; Daud, AI; Marchion, DC; Munster, PN; Sullivan, DM | 1 |
| Carraway, HE; Gore, SD | 1 |
| Bicaku, E; Chiappori, A; Daud, A; DeConti, R; Fishman, M; Garrett, C; Lee, JH; Lush, R; Marchion, D; Minton, S; Münster, P; Schmitt, M; Simon, G; Sullivan, D | 1 |
| Bicaku, E; Centeno, B; Daud, A; Kim, J; Lacevic, M; Marchion, D; Minton, S; Munster, P; Neuger, A; Sullivan, D | 1 |
2 review(s) available for valproic acid and epirubicin
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for valproic acid and epirubicin
| Article | Year |
|---|---|
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Female; Histone Deacetylase Inhibitors; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Survival Rate; Topoisomerase II Inhibitors; Treatment Outcome; Valproic Acid | 2007 |
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cyclophosphamide; Enzyme Inhibitors; Epirubicin; Female; Fluorouracil; Histone Deacetylase Inhibitors; Histones; Humans; Leukocytes; Male; Middle Aged; Neoplasms; Valproic Acid | 2009 |
9 other study(ies) available for valproic acid and epirubicin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspases; Down-Regulation; Drug Resistance, Neoplasm; Epirubicin; fas Receptor; Histone Deacetylase Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Glycoproteins; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Valproic Acid | 2006 |
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.
Topics: Acetylation; Animals; Breast Neoplasms; Cell Line, Tumor; Chromatin; Comet Assay; Enzyme Inhibitors; Epirubicin; Female; Histone Deacetylase Inhibitors; Histones; Humans; Mice; Mice, Nude; Microscopy, Electron; Topoisomerase II Inhibitors; Valproic Acid | 2005 |
Addition of histone deacetylase inhibitors in combination therapy.
Topics: Antibiotics, Antineoplastic; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Histone Deacetylase Inhibitors; Humans; Neoplasms; Topoisomerase II Inhibitors; Valproic Acid | 2007 |